$120MRound, 21 November 2025
Funds phase 1b proof-of-concept for lead ADCs SLV-154 and SLV-324.
- Amount
- $120M
- Announced
- 21 November 2025
- Lead
- Yosemite
- Other investors
- MSD, Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, SymBiosis
- Use of funds
- Funds phase 1b proof-of-concept for lead ADCs SLV-154 and SLV-324.
- Checked
- Amount and date checked against the press source
- Source
- Solve Therapeutics raises $120M for ADC pipeline pharmaphorum.com